Key points are not available for this paper at this time.
More than a decade after the initial clinical reports of chimeric antigen receptor (CAR) T-cell therapy emerging from early-phase trials and individual case studies 1 , 2 , 3 . CAR T cells directed against B-cell maturation antigen (BCMA) have now evolved into an established standard of care for patients with relapsed or refractory multiple myeloma (RRMM) 4 .
Merz et al. (Tue,) studied this question.